Unlock Premium Data: Up to 50% Off InvestingProCLAIM SALE

Barclays lowers AbbVie shares target on Humira sales erosion concerns

EditorEmilio Ghigini
Published 2024-04-29, 05:50 a/m

On Monday, Barclays (LON:BARC) made an adjustment to its outlook on AbbVie (NYSE:ABBV) shares, reducing the price target to $187 from the previous $195. The firm maintained its Overweight rating on the NYSE:ABBV stock.

The revision was attributed to anticipated erosion of sales for Humira, a key drug in AbbVie's portfolio, along with temporary challenges that are expected to affect the company's earnings per share (EPS) growth for the year 2025.

The pharmaceutical company, known for its biopharmaceutical products, has been facing concerns over the competition for Humira, which has been a significant revenue generator. The lowered price target reflects adjustments in the growth projections due to these concerns. Despite this, Barclays continues to hold a favorable long-term view on AbbVie's stock.

The analyst from Barclays highlighted the factors influencing the revised price target, noting that while there are immediate headwinds, the long-term growth profile for AbbVie remains positive. The comment from the analyst indicated a belief in the company's ability to navigate through the current challenges and continue to grow in the long term.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.